Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Adverum Biotechnlgs (ADVM)
Adverum Biotechnlgs (ADVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Adverum Biotechnologies: Q3 Earnings Snapshot

Adverum Biotechnologies: Q3 Earnings Snapshot

ADVM : 0.8087 (-1.38%)
Adverum Biotechnologies: Q2 Earnings Snapshot

Adverum Biotechnologies: Q2 Earnings Snapshot

ADVM : 0.8087 (-1.38%)
Adverum Biotechnologies: Q1 Earnings Snapshot

Adverum Biotechnologies: Q1 Earnings Snapshot

ADVM : 0.8087 (-1.38%)
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?

Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.

ADIL : 2.19 (+2.82%)
ADVM : 0.8087 (-1.38%)
Rumble, Braze rise; Virgin Orbit, Sientra fall

Stocks that traded heavily or had substantial price changes Friday: Rumble, Braze rise; Virgin Orbit, Sientra fall

ADVM : 0.8087 (-1.38%)
SIEN : 0.8227 (-1.95%)
BB.TO : 4.98 (-2.73%)
NKLA : 0.9724 (-3.72%)
Adverum Biotechnologies: Q4 Earnings Snapshot

Adverum Biotechnologies: Q4 Earnings Snapshot

ADVM : 0.8087 (-1.38%)
Adverum Biotechnologies: Q3 Earnings Snapshot

Adverum Biotechnologies: Q3 Earnings Snapshot

ADVM : 0.8087 (-1.38%)
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study

Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.

REGN : 823.81 (+1.88%)
DVAX : 13.70 (+2.47%)
BAYRY : 8.5200 (+1.91%)
ADVM : 0.8087 (-1.38%)
Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference

REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish...

ADVM : 0.8087 (-1.38%)
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish...

ADVM : 0.8087 (-1.38%)

Barchart Exclusives

Live Cattle Supply Challenges Still Persist and Support a Seasonal Buy Opportunity
The cattle market continues to experience a period of constrained supplies, a trend expected to persist in the coming year. The fundamentals of the challenges caused by a drought and elevated input prices have not changed. The recent sell-off in Live Cattle may have created a seasonal buy pattern worth investigating. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar